167 related articles for article (PubMed ID: 16324815)
1. The removal of Cremophor EL from paclitaxel for quantitative analysis by HPLC-UV.
Perdue JD; Seaton PJ; Tyrell JA; DeVido DR
J Pharm Biomed Anal; 2006 Apr; 41(1):117-23. PubMed ID: 16324815
[TBL] [Abstract][Full Text] [Related]
2. HPLC method for the determination of carboplatin and paclitaxel with cremophorEL in an amphiphilic polymer matrix.
Mittal A; Chitkara D; Kumar N
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Aug; 855(2):211-9. PubMed ID: 17543592
[TBL] [Abstract][Full Text] [Related]
3. Effect of unpurified Cremophor EL on the solution stability of paclitaxel.
Gogate US; Schwartz PA; Agharkar SN
Pharm Dev Technol; 2009; 14(1):1-8. PubMed ID: 18791935
[TBL] [Abstract][Full Text] [Related]
4. Simple assessment of homogeneity in pharmaceutical mixing processes using a near-infrared reflectance probe and control charts.
Skibsted ET; Boelens HF; Westerhuis JA; Witte DT; Smilde AK
J Pharm Biomed Anal; 2006 Apr; 41(1):26-35. PubMed ID: 16289623
[TBL] [Abstract][Full Text] [Related]
5. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel nanoparticles for the potential treatment of brain tumors.
Koziara JM; Lockman PR; Allen DD; Mumper RJ
J Control Release; 2004 Sep; 99(2):259-69. PubMed ID: 15380635
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
[TBL] [Abstract][Full Text] [Related]
8. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Brouwer E; Verweij J; Hauns B; Loos WJ; Nooter K; Mross K; Stoter G; Sparreboom A
Anal Biochem; 1998 Aug; 261(2):198-202. PubMed ID: 9716422
[TBL] [Abstract][Full Text] [Related]
9. Comparison of UV spectrophotometric method and high performance liquid chromatography for the analysis of flunarizine and its application for the dissolution test.
Busaranon K; Suntornsuk W; Suntornsuk L
J Pharm Biomed Anal; 2006 Apr; 41(1):158-64. PubMed ID: 16352415
[TBL] [Abstract][Full Text] [Related]
10. A HPLC validated assay of paclitaxel's related impurities in pharmaceutical forms containing Cremophor EL.
Ciutaru D; Badea I; Lazara L; Nicolescu D; Tudose A
J Pharm Biomed Anal; 2004 Feb; 34(3):493-9. PubMed ID: 15127804
[TBL] [Abstract][Full Text] [Related]
11. Taxol(®)-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor(®) EL.
Vader P; Fens MH; Sachini N; van Oirschot BA; Andringa G; Egberts AC; Gaillard CA; Rasmussen JT; van Wijk R; van Solinge WW; Schiffelers RM
Nanomedicine (Lond); 2013 Jul; 8(7):1127-35. PubMed ID: 23384701
[TBL] [Abstract][Full Text] [Related]
12. Use of (1)H NMR to facilitate solubility measurement for drug discovery compounds.
Lin M; Tesconi M; Tischler M
Int J Pharm; 2009 Mar; 369(1-2):47-52. PubMed ID: 19073245
[TBL] [Abstract][Full Text] [Related]
13. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
[TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process.
Park JH; Yan YD; Chi SC; Hwang DH; Shanmugam S; Lyoo WS; Woo JS; Yong CS; Choi HG
J Pharm Pharmacol; 2011 Apr; 63(4):491-9. PubMed ID: 21401600
[TBL] [Abstract][Full Text] [Related]
15. Solubilization of Paclitaxel (taxol) by peptoad self-assemblies.
Menger FM; Zhang H; de Joannis J; Kindt JT
Langmuir; 2007 Feb; 23(5):2308-10. PubMed ID: 17274639
[TBL] [Abstract][Full Text] [Related]
16. Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
El Nemr S; Al-Najjar BY; Omer HK; Elhissi AMA; Alhnan MA
Pharm Dev Technol; 2018 Jan; 23(1):67-75. PubMed ID: 28696155
[TBL] [Abstract][Full Text] [Related]
17. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Sparreboom A; van Tellingen O; Huizing MT; Nooijen WJ; Beijnen JH
J Chromatogr B Biomed Appl; 1996 Jun; 681(2):355-62. PubMed ID: 8811447
[TBL] [Abstract][Full Text] [Related]
18. The use of mixed-mode ion-exchange solid phase extraction to characterize pharmaceutical drug degradation.
Landis MS
J Pharm Biomed Anal; 2007 Sep; 44(5):1029-39. PubMed ID: 17553650
[TBL] [Abstract][Full Text] [Related]
19. Quantitative determination of anti-tumor agent bis(4-fluorobenzyl)trisulfide, fluorapacin and its pharmaceutical preparation by high-performance liquid chromatography.
Bao Y; He Y; Xu X; Mo X; Xu X; Wang X; An H
J Pharm Biomed Anal; 2008 Jan; 46(1):206-10. PubMed ID: 17964749
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Sparreboom A; Loos WJ; Verweij J; de Vos AI; van der Burg ME; Stoter G; Nooter K
Anal Biochem; 1998 Jan; 255(2):171-5. PubMed ID: 9451500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
